Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hisako Yoshida

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 24, 2020
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignShinya Fujiki, Kenichi Iijima, Masaaki Okabe, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Yohei Doi, Masaya Hibino, Ryota Hase, et al.
Trials|January 8, 2021
Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)Yasuaki Nagami, Taishi Sakai, Masafumi Yamamura, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 24, 2020
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignShinya Fujiki, Kenichi Iijima, Masaaki Okabe, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2020
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Yohei Doi, Masaya Hibino, Ryota Hase, et al.
Trials|January 8, 2021
Continuous warfarin administration versus heparin bridging therapy in post colorectal polypectomy haemorrhage: a study protocol for a multicentre randomised controlled trial (WHICH study)Yasuaki Nagami, Taishi Sakai, Masafumi Yamamura, et al.
Pageof 14